Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971497 | 0.95 | STAT3 (0.46) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL29979612 | 0.93 | STAT3 (0.47) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL29980044 | 0.93 | ALDH1A1 (0.45) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL19987083 | 0.93 | STAT3 (0.47) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL19971528 | 0.93 | ALDH1A1 (0.45) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL19986908 | 0.91 | ALDH1A1 (0.49) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL7005531 | 0.88 | STAT3 (0.47) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL3236130 | 0.88 | KMT2A (0.48) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL18313042 | 0.87 | MAPT (0.45) | STAT3KDM4EHPGDKMT2ACYP2C19 | |
| SCHEMBL8091107 | 0.87 | NPC1 (0.48) | STAT3KDM4EHPGDKMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115554294-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115477649-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115429798-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| CN-109689656-B | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| EP-3512849-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | STAT3 3786/4885KDM4E 3765/4885HPGD 908/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | STAT3 3786/4885KDM4E 3765/4885HPGD 908/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | STAT3 3786/4885KDM4E 3765/4885HPGD 908/4885 |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | STAT3 3786/4885KDM4E 3765/4885HPGD 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.